Skip to content
Download PDF

Diabetes Mellitus: Complications

Chapter 417 | Part 12: Endocrinology and Metabolism · Part 12 – Endocrinology & Metabolism · Chapter 417

Key Clinical Points

  1. Microvascular complications (retinopathy, neuropathy, nephropathy) result from chronic hyperglycemia; macrovascular complications (ASCVD, PAD, CVD) share pathophysiology with the general population but are accelerated by insulin resistance.
  2. The 'metabolic memory' (legacy effect) means improved glycemic control for ≥10 years provides lasting protection against complications even after control is no longer maintained.
  3. Blood pressure target is <130/80 mmHg; ACE inhibitors or ARBs are preferred if albuminuria is present.
  4. SGLT2 inhibitors reduce CKD progression and cardiovascular events; GLP-1 receptor agonists (e.g., semaglutide) improve kidney outcomes and reduce CV death.
  5. Retinopathy screening begins 5 years after type 1 DM onset or at diagnosis of type 2 DM; annual dilated eye exams are required.
  6. Neuropathy screening begins 5 years after type 1 DM onset or at diagnosis of type 2 DM, specifically targeting loss of protective sensation (LOPS).
  7. Gestational diabetes mellitus (GDM) affects ~7% (range 1–14%) of pregnancies; screening is recommended between weeks 24 and 28.
  8. Pregnancy in known DM requires a target HbA1c <6.5% to minimize the risk of fetal malformations (increased 4-10 times with uncontrolled DM).
  9. Transient worsening of established retinopathy may occur during the first 6-12 months of improved glycemic control.
  10. Diabetic nephropathy is the leading cause of chronic kidney disease (CKD) and stage 5 CKD requiring renal replacement therapy.
  11. Avoidance of hypoglycemia is critical in older adults; HbA1c goals may be <8.0–8.5% for those with complex health or cognitive impairment.
  12. Diagnosis of diabetic neuropathy must only be made after other potential etiologies are excluded.

DEFINITION & OVERVIEW

• Overview: ◦ Complications affect multiple organ systems and are the primary drivers of morbidity and mortality. ◦ Timing: ◦ Microvascular complications: Usually appear in the second decade of hyperglycemia. ◦ Macrovascular complications: May develop before hyperglycemia is established due to insulin resistance and associated dyslipidemia.

• Classification (Table 417-1): ◦ Microvascular (Diabetes-specific): ◦ Eye disease (Retinopathy [nonproliferative/proliferative], Macular edema, Cataracts, Glaucoma) ◦ Neuropathy (Sensory and motor [mono- and polyneuropathy], Autonomic) ◦ Nephropathy (Albuminuria and declining renal function) ◦ Macrovascular (Shared pathophysiology): ◦ Coronary heart disease ◦ Peripheral arterial disease (PAD) ◦ Cerebrovascular disease ◦ Heart failure ◦ Other: ◦ Gastrointestinal (gastroparesis, diarrhea) ◦ Genitourinary (uropathy/sexual dysfunction) ◦ Dermatologic, Infectious ◦ Cataracts, Glaucoma ◦ Cheiroarthropathy, Periodontal disease, Hearing loss ◦ Comorbidities (Uncertain link to hyperglycemia): ◦ Depression, Obstructive sleep apnea, Fatty liver disease, Hip fracture, Osteoporosis, Cognitive impairment or dementia, Low testosterone in men.

EPIDEMIOLOGY & RISK FACTORS

• Age of Diagnosis: Earlier diagnosis of type 2 DM increases complication risk; → estimated 3-4 years reduced life expectancy for every decade of earlier diagnosis. • Nephropathy Prevalence: 20–40% of patients with diabetes develop diabetic nephropathy. • Risk Factors for Nephropathy: ◦ Family history ◦ Genetic/environmental factors ◦ Smoking (accelerates renal decline) • Risk Factors for Peripheral Neuropathy: ◦ ASCVD, elevated triglycerides, and hypertension. • Demographics: Diabetic nephropathy and stage 5 CKD are more common in Black, Native American, and Hispanic individuals.

ETIOLOGY & PATHOPHYYSICOLOGY

• Primary Driver: Chronic hyperglycemia (multifactorial mechanism of cellular/organ dysfunction). • Proposed Mechanisms: ◦ Epigenetic changes influencing gene expression. ◦ Advanced glycosylation end products (AGEs; e.g., pentosidine, glucosepane, and carboxymethyllysine) → bind to receptors or nonenzymatically glycosylate proteins → cross-linking, glomerular dysfunction, endothelial dysfunction, and accelerated atherosclerosis. ◦ Reactive oxygen species/superoxide production in mitochondria → activate multiple pathways. • Growth Factors: ◦ VEGF-A: Increased locally in proliferative retinopathy; target of intravitreous injection therapy. • Macrovascular Pathophysiology: Includes insulin resistance (present years before T2DM diagnosis), inflammation, and dyslipidemia. • Lipid Accumulation: Insulin failure to suppress lipolysis → increased fatty acids to liver/muscle/endothelium → accumulation of triglycerides, diacylglycerol, and ceramides.\ • Metabolic Memory (Section 2.1): ◦ Defined as the 'legacy effect' where a period of improved glycemic control (e.g., in DCCT or UKPDS) provides protection for ≥10 years even after control is no longer maintained.

CLINICAL FEATURES

• Ophthalmologic Complications: • Retinopathy: ◦ Nonproliferative: Typically appears in 1st or 2nd decade of hyperglycemia; features include microaneurysms, blot hemorrhages, and cotton-wool spots. ◦ Proliferative: Hallmark is neovascularization (response to hypoxia); can lead to vitreous hemorrhage, fibrosis, and retinal detachment. ◦ Risk Factors: Duration of DM, glycemic control (primary), hypertension, nephropathy, and dyslipidemia. • Renal Complications: ◦ Diabetic Nephropathy: Leading cause of CKD and stage 5 CKD. ◦ T1DM vs T2DM: Association with retinopathy is stronger in T1DM; presence of CKD without retinopathy in T1DM should prompt investigation for other causes. ◦ Renal Tubular Acidosis: Type IV (hyporeninemic hypoaldosteronism) may occur in both types → risk of hyperkalemia and acidemia (exacerbated by ACEi, ARBs, or MRAs). ◦ Radiocontrast Risk: Patients are predisposed to radiocontrast-induced nephrotoxicity; requires pre/post hydration and 24–48 h creatinine monitoring. • Neuropathy: ◦ Prevalence: ~50% of patients with long-standing DM. ◦ Types: Diffuse (distal symmetrical polyneuropathy, autonomic), mononeuropathy, or radiculopathy/polyradiculopathy. ◦ Risk Factors: Duration of DM, glycemic control, BMI (higher = higher risk), and smoking. • Reproductive Issues: ◦ GDM: Affects ~7% (range 1–14%) of pregnancies; increased in Black and Hispanic groups. ◦ Fetal Impact: High maternal glucose is a teratogen → fetal hyperinsulinemia → macrosomia. ◦ Post-partum: Most revert to normal, but some remain at risk for obesity/glucose intolerance. Children of women with GDM are at risk for obesity and glucose intolerance in later adolescence.

DIFFERENTIAL DIAGNOSIS

• Neuropathy: Diagnosis must be made only after excluding other possible etiologies. • Nephropathy: In T1DM, the presence of CKD without retinopathy should prompt investigation for alternative causes of kidney disease.

DIAGNOSTIC APPROACH

  1. Retinopathy Screening: ◦ Timing: Start 5 years after T1DM onset OR at time of T2DM diagnosis. ◦ Requirement: Annual dilated eye exams are required (non-dilated exams are inadequate).
  2. Neuropathy Screening: ◦ Timing: Start 5 years after T1DM onset OR at time of T2DM diagnosis. ◦ Goal: Detect loss of protective sensation (LOPS).
  3. Nephropathy Assessment: ◦ Red Flag: Presence of CKD without retinopathy in T1DM → prompt investigation for alternative causes of kidney disease.

MANAGEMENT & TREATMENT

  1. Glycemic Control: Primary prevention for retinopathy and nephropathy.
  2. Blood Pressure Management: ◦ Target: <130/80 mmHg. ◦ Pharmacotherapy: ACE inhibitors or ARBs are preferred if albuminuria is present.
  3. Pharmacotherapy for Renal & CV Protection: ◦ SGLT2 inhibitors: Reduce CKD progression and cardiovascular events. ◦ GLP-1 receptor agonists (e.g., semaglutide): Improve kidney outcomes and reduce CV death.
  4. Elderly Population Management: ◦ Priority: Avoidance of hypoglycemia. ◦ HbA1c Target: <8.0–8.5% for those with complex health or cognitive impairment.

PROGNOSIS & COMPLICATIONS

• DCCT/UKPDS Findings: ◦ Intensive glycemic control provides a 'metabolic memory' (legacy effect) of ≥10 years. ◦ Significant reductions in retinopathy, albuminuria, clinical nephropathy, and neuropathy with intensive management.

SPECIAL CONSIDERATIONS

• Retinopathy Paradox: During first 6–12 months of improved glycemic control, established retinopathy may transiently worsen. • GLP-1 Warning: Risk of worsening retinopathy with rapid glycemic improvement; use caution in patients with existing retinopathy. • Nephropathy & Glycemia: Once moderate albuminuria is established, improved glycemic control has less impact on slowing progression.

KEY PEARLS & CLINICAL TRAPS

• Early Diagnosis: T2DM diagnosed at a younger age leads to significantly higher complication rates (3-4 years less life expectancy per decade earlier). • Retinopathy Paradox: Transient worsening during first 6–12 months of improved control is expected. • GLP-1 Warning: Use caution in patients with existing retinopathy when using GLP-1 agonists for rapid glycemic improvement. • Nephropathy & Glycemia: Once moderate albuminuria is established, improved glycemic control has less impact on slowing progression.

Reference Tables

Harrison's 22e, p.3222

  • Microvascular
  • Eye disease
  • Retinopathy (nonproliferative/proliferative)
  • Macular edema
  • Neuropathy
  • Sensory and motor (mono- and polyneuropathy)
  • Autonomic
  • Nephropathy (albuminuria and declining renal function)
  • Macrovascular
  • Coronary heart disease
  • Peripheral arterial disease
  • Cerebrovascular disease
  • Heart failure
    Other
  • Gastrointestinal (gastroparesis, diarrhea)
  • Genitourinary (uropathy/sexual dysfunction)
  • Dermatologic
  • Infectious
  • Cataracts
  • Glaucoma
  • Cheiroarthropathya
  • Periodontal disease
  • Hearing loss
  • Other comorbid conditions associated with type 1 or type 2 diabetes (relationship
    to hyperglycemia is uncertain): depression, obstructive sleep apnea, fatty liver
    disease, hip fracture, osteoporosis, cognitive impairment or dementia, low
    testosterone in men